UCB (UCBJY) Projected to Post Quarterly Earnings on Thursday
by Sarita Garza · The Markets DailyUCB (OTCMKTS:UCBJY – Get Free Report) is anticipated to release its results before the market opens on Thursday, February 26th. Analysts expect UCB to post earnings of $2.98 per share and revenue of $4.9258 billion for the quarter.
UCB Price Performance
UCB stock opened at $159.09 on Tuesday. UCB has a one year low of $71.16 and a one year high of $168.76. The company has a quick ratio of 1.01, a current ratio of 1.35 and a debt-to-equity ratio of 0.29. The business has a fifty day moving average price of $150.40 and a 200-day moving average price of $137.49.
Wall Street Analysts Forecast Growth
Separately, Zacks Research downgraded UCB from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 3rd. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, UCB presently has a consensus rating of “Buy”.
Get Our Latest Stock Report on UCBJY
UCB Company Profile
UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.
The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.